Seeley was just weeks old when she was diagnosed with acute myeloid leukemia, a rare and aggressive blood and bone marrow cancer.

Key TakeawaysA highly sensitive DNA test can detect hidden leukemia cells that predict if a patient’s cancer is likely to returnPatients with the NPM1 mutation before a transplant were three to four ...

From a study that analyzed the therapeutic dilemma of treating acute leukemia (AL) during pregnancy and the delicate balance of improving maternal and fetal outcomes, investigators determined that ...

The communications executive was instrumental in launching RuPaul's Drag Race and supporting the MTV Video Music Awards throughout his influential career.

Acute Myeloid Leukemia is the most common acute leukemia in adults affecting 2-6 adults per 100,000k globally.​ -With relapse rates as high as 50%, routine measurable residual disease (MRD) ...

Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, ...

New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released the next segment on its CEO Corner, a platform featuring Walter Klemp, Chief Executive Officer.

Selected as a C-Further program with up to $1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial ...

Aptevo Therapeutics Inc. (NASDAQ:APVO) shares plunged about 18% on Tuesday even after the company reported promising interim clinical results for its acute myeloid leukemia (AML) treatment candidate, ...

Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine ...